




COVID-19 therapeutics update for HCCs

JUNE 7, 2022

Agenda

- 1 Overview of therapeutics (Tx) options and guidance on how LTCFs can access products
- 2 Findings from DOH's Tx prescriber survey
- 3 Opportunities for HCCs and LTC stakeholders to support Tx efforts

3 COVID-19 outpatient Tx are government-allocated across PA

	Pre-exposure Prophylaxis (PrEP) 	Monoclonal Antibodies (mAbs) ¹ 	Oral antivirals (OAVs) 
Product(s)	• Evusheld (AstraZeneca)	• bebtelovimab (Eli Lilly)	• Lagevrio (Merck) • Paxlovid (Pfizer)
Who should get them	• Immunocompromised patients w/ negative COVID-19 test & no known exposure	• Non-hospitalized COVID-19 patients	• Non-hospitalized COVID-19 patients
Treatment window	• Pre-exposure	• 7 days from symptom onset	• 5 days from symptom onset
Route of administration	• Two intramuscular injections	• IV injection	• Oral tablets taken twice daily for five days
PA sites currently reporting product available ²	• ~85 sites	• ~60 sites	• ~1,500 sites for Lagevrio • ~1,660 sites for Paxlovid

1. De-authorized mAbs for treatment as of 4/26/2022 due to inefficacy against Omicron BA.1/BA.2: sotrovimab, bam/ete, REGEN-COV

2. Based on self-reported data by sites to HPOP, as published on HealthData.gov. Likely undercounts total # of sites with product on-hand given reporting gaps
Source: Manufacturer product EUAs, NIH COVID-19 treatment guidelines, NEJM, ASPR, Healthdata.gov

LTCFs can access COVID-19 Tx in three ways

If your LTCF has...

Action

A pharmacy on-site and/or the ability to prescribe & dispense Tx on-site

- Complete DOH [enrollment form](#)
- Create Health Partner Ordering Portal (HPOP) account w/ support from DOH
- Place Tx order request on HPOP¹

A pharmacy partner to dispense Tx

- Check if pharmacy dispenses COVID-19 Tx using [federal locator](#) or [DOH website](#)
- If pharmacy doesn't dispense COVID-19 Tx, encourage them to [enroll](#) in PA DOH COVID-19 Tx distribution network

None of the above

- Submit request for oral antivirals from DOH state reserve
 - SNFs can request direct shipment
 - Doctor's prescription still required

3 1. Tx product requests must be submitted on HPOP by Monday 11:59 pm to be considered for allocation in a given weekly cycle; order requests placed after deadline will be considered in the following week's cycle

Summary – Tx prescriber survey

Survey context

- Conducted survey of PA prescribers in May 2022 to better understand Tx prescribing behaviors, barriers to use, and opportunities for improvement
- Over 2,000 respondents across provider types
 - ~50% hospitals/health systems vs. other types
 - Mix of primary, acute, outpatient, & emergency care


Emerging findings

- **Oppty to improve prescribing levels** across Tx, esp. PrEP
- Top mutual barriers across products center on **lack of information** and **difficulties accessing product**
- Key levers DOH can pull to address barriers include ramping up **provider & patient education** and improving **awareness of & ability to readily access** product

Differences in prescribing behaviors exist across Tx; Paxlovid most commonly prescribed, larger prescribing gap for Evusheld

What best describes your prescribing behavior of this product for eligible patients?

% of respondents (n=1707)¹



Key takeaways

>50% of providers prescribing Paxlovid

Relative prescribing behavior across products aligns with expectations

- Paxlovid most prescribed, likely given:
 - Superior efficacy (vs. Lagevrio)
 - Easier access (vs. mAbs)
- Evusheld less prescribed than Paxlovid & mAbs, likely given narrower indication

To increase prescribing rates across Tx, need to overcome key barriers cited...


Lack of information on products & perceptions around limited supply & accessibility cited as key barriers to Tx prescribing

What concerns or barriers are limiting your prescribing of the following Tx? Select all that apply (n = 2018)

Paxlovid



Evusheld




■ Product concerns
 ■ Patient-specific
 ■ Access
 ■ Lack of information
 ■ Procedural/structural

More provider/patient education and broader Tx access would help address barriers in prescribing COVID-19 Tx


What sources do you consider when prescribing COVID-19 therapeutics for your patients? (Select all that apply)

% of respondents (n=2018)



What additional resources would best support you in prescribing COVID-19 therapeutics? (Select all that apply)

% of respondents (n=2018)



Key levers for DOH


Drive **greater awareness & understanding** of available Tx options for both providers & patients

- Influence providers via medical assoc. & peer champions
- Enhance public msg.

Ensure **broad Tx access**

- Continue expanding network by enrolling new sites
- Increase awareness of tools to locate Tx

Action items for HCCs & LTC stakeholders



Boost awareness

- Share **LTCF Tx one-pager** & "**Caught COVID**" Tx flyer with LTCF admin. & healthcare providers
 - *To be shared by email after call*
- Direct patients & providers to **relevant Tx resources**
 - DOH resources: [website](#), [Tx distribution handbook](#)
 - Federal resources: [ASPR](#), [CDC](#), [NIH](#)



Improve access

- **Identify facilities** that can administer/dispense Tx & **help them get enrolled** in DOH's Tx network
- Direct providers to federal [COVID-19 Tx locator tool](#)
- Guide patients to [federal Test to Treat sites](#) to receive testing, evaluation, & prescription for OAVs in one place



Double-down on equity

- **Educate** vulnerable & underserved patients (& providers with access to these populations) on available Tx options, especially Evusheld/PrEP

For discussion / post in the chat:

What else can HCCs do to support Tx awareness, access, & equity?

Contact us at:
covidtherapeutics@pa.gov



pennsylvania
DEPARTMENT OF HEALTH